Leerink Swann Downgrades Cardiome Pharma (CRME) to Market Perform
Tweet
Share
E-mailGet Alerts CRME Hot Sheet
Price: $2.33 --0%
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Join SI Premium – FREE
Leerink Swann downgraded Cardiome Pharma (NASDAQ: CRME) to Market Perform with a price target of $1 (down form $9).
The firm said probability of approval for oral vernakalant decreases to 0% from 50% previously after Merck's discontinuation.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
Shares of Cardiome Pharma closed at $0.88 yesterday.
The firm said probability of approval for oral vernakalant decreases to 0% from 50% previously after Merck's discontinuation.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
Shares of Cardiome Pharma closed at $0.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- Skandinaviska Enskilda Banken AB (SEBA:SS) (SKVKY) PT Raised to SEK190 at JPMorgan
- Prosus NV (PRX:NA) (PROSY) PT Lowered to EUR68 at Barclays
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
